Premium
Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade
Author(s) -
Mack Philip C.,
Chi SungGil,
Meyers Frederick J.,
Stewart Susan L.,
deVere White Ralph W.,
Gumerlock Paul H.
Publication year - 1998
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/(sici)1097-0045(19980201)34:2<145::aid-pros10>3.0.co;2-i
Subject(s) - prostate cancer , prostate , androgen , medicine , blockade , cancer , messenger rna , gene expression , exon , biology , endocrinology , oncology , gene , hormone , receptor , genetics
BACKGROUND The RB1 proliferation control pathway is a critical determinant of cell cycle progression. Abnormalities of RB1 are found in a variety of cancers, and the association with human prostate cancer (CaP) was examined here. METHODS RNA expression levels of RB1 in CaPs were examined by RT‐PCR. RNA integrity was assessed by evaluating expression of an endogenous gene standard. RESULTS Abnormally low RB1 mRNA expression was found in 12/33 (36%) of CaPs from patients who had received combined androgen blockade (CAB) treatment. In contrast, 6/48 (13%) untreated CaPs showed abnormally low expression. This difference was statistically significant ( P = 0.015). In the samples from untreated patients, a higher frequency of abnormal RB1 was found in specimens with a higher Gleason grade ( P = 0.038). In addition, one untreated stage C, grade 9 specimen was found to express RB1 transcripts lacking exon 22, as determined by sequencing of DNA from the truncated transcripts. CONCLUSIONS These findings suggest that abnormalities of RB1 may contribute to hormone‐withdrawal‐related survival of CaP cells. Prostate 34:145–151, 1998. © 1998 Wiley‐Liss, Inc.